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Objectives The aim of the study was to examine the predictive value of QRS duration and morphology during watchful wait-
ing in asymptomatic patients with aortic stenosis (AS).
Background QRS duration and morphology are associated with poor prognosis in many different populations, but the predic-
tive value, particularly of the risk of sudden cardiac death (SCD), in asymptomatic patients with AS has not been
well studied.
Methods Data were obtained in asymptomatic AS patients randomized to simvastatin/ezetimibe combination versus pla-
cebo in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study. The impact of QRS duration, evaluated as
a categorical variable of 85 ms versus 85 to 99 ms and 100 ms (excluding bundle branch block [BBB]) and
QRS morphology in those with BBB, on cardiovascular morbidity and mortality was assessed by adjusting for
clinical and echocardiographic covariates.
Results QRS data were available in 1,542 patients who were followed for a mean of 4.3  0.8 years (6,631 patient-
years of follow-up). There were 68 cardiovascular deaths (4.6%), including 27 SCDs (1.8%). QRS duration was
85 ms in 900 patients (58.4%), 85 to 99 ms in 396 (25.7%), 100 ms in those without BBB in 144 (9.3%),
and 102 (6.6%) in those with BBB. In multivariable analyses, those with QRS duration 100 ms had, compared
with those with QRS duration 85 ms, a 5-fold higher risk of SCD (95% confidence interval: 1.8 to 13.7,
p  0.002) and a 2.5-fold higher risk of cardiovascular death (95% confidence interval: 1.2 to 5.1, p  0.01).
Conclusions QRS duration and morphology in asymptomatic patients with AS are independently associated with a poor prog-
nosis, particularly the risk of SCD. (Simvastatin Ezetimibe in Aortic Stenosis [SEAS]; NCT00092677)
(J Am Coll Cardiol 2012;59:1142–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.020The increased afterload associated with aortic stenosis (AS)
initially induces compensatory left ventricular (LV) hyper-
trophy and ultimately results in impaired LV systolic func-
tion as well as symptoms of heart failure (1). The onset of
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(AVR) (2). The annual risk of sudden cardiac death (SCD)
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criteria for AVR (3). Therefore, predictors of adverse
outcome, and in particular SCD, are of special interest in
asymptomatic AS because they may lead to a better selection
of patients for AVR, perhaps reducing the risk of adverse
outcome and prevention of SCD. In this regard, increased
QRS duration is appealing because it has been shown to be
associated with LV hypertrophy and the risk of congestive
heart failure in the general population as well as the risk of
SCD in patients with increased afterload due to hyperten-
sion or with impaired LV ejection fraction (4–7). Moreover,
it is a low-cost, easily obtainable, and reproducible param-
eter. Several studies have suggested differing etiologies of
left bundle branch block (LBBB), which is associated with
LV dysfunction, right bundle branch block (RBBB), often
in the absence of overt heart disease, and prolonged QRS
duration not meeting the criteria for bundle branch block
(BBB) (8). However, the association of QRS duration,
especially lesser degrees of QRS prolongation (120 ms),
with the risk of adverse outcome, particularly SCD, and the
additive value of QRS morphology, in those with BBB,
have not been well studied in asymptomatic patients with
AS. Thus, the present study investigated whether: 1) QRS
duration in patients without BBB is related to the risk of
cardiovascular morbidity and mortality, particularly of SCD;
and 2) QRS morphology in those with BBB added prog-
nostic information during long-term follow-up in asymp-
tomatic patients with mild to moderate AS and preserved
LV systolic function.
Methods
Study population. The SEAS (Simvastatin Ezetimibe in
Aortic Stenosis) study was a multicenter, randomized,
double-blind, placebo-controlled study investigating
whether intensive lipid-lowering with simvastatin/ezetimibe
combination compared with placebo could reduce the need
for AVR and the risk of cardiovascular morbidity and
mortality in 1,873 patients from ages 45 to 85 years with
asymptomatic mild to moderate AS (defined as echocardio-
graphic aortic valve thickening accompanied by a Doppler-
measured aortic peak flow velocity 2.5 and 4.0 m/s and
normal systolic LV function). The main outcome including
study design, organization, clinical measures, exclusion cri-
teria (most important systolic heart failure, diabetes, and
known ischemic heart disease), baseline characteristics, and
main outcome were published previously (9,10). This study
uses pre-specified analyses of prospectively collected data
from the SEAS and the SEAS electrocardiographic sub-
study to investigate whether QRS duration is independently
associated with the risk of SCD, overall cardiovascular
death, cardiovascular morbidity, AVR, and all-cause mor-
tality in asymptomatic patients with AS. This study com-
plies with the Declaration of Helsinki, and locally appointed
ethics committees approved the research protocol, and
informed consent was obtained from all participants. dElectrocardiography. Electro-
cardiographic study protocol,
reading procedures, and repro-
ducibility were published (11). In
short, electrocardiograms were
recorded at the local study cen-
ters at a paper speed of 25 or 50
mm/s, after which they were sent
to the central electrocardiogram
core laboratory at The Heart
Center, Rigshospitalet, Copen-
hagen, Denmark. A physician,
blinded to the randomization
and all clinical data, read and
transferred all electrocardiograms
directly to an electrocardiogram
database, using Minnesota codes,
in agreement with recent recommendations (12). QRS
duration was measured in the lead with the greatest QRS
width. Patients were grouped according to: 1) QRS dura-
tion 85 ms; 2) QRS duration 85 to 99 ms; 3) QRS
duration100 ms (excluding patients with BBB); 4) LBBB; and
5) RBBB with and without left anterior fascicular block.
Echocardiography. The echocardiographic study protocol,
reading procedures, and reproducibility were published (13).
In short, transthoracic echocardiograms were read blinded
at the SEAS echocardiography core laboratory at Hauke-
land University Hospital in Bergen, Norway. The aortic
valve area was calculated using the continuity equation, in
accordance with recent recommendations (14). Quantitative
echocardiography was performed according to American
Society of Echocardiography guidelines (15).
Endpoints. All endpoints were classified by an endpoint
committee blinded to a randomization group with a pre-
specified endpoint manual prepared by the SEAS steering
committee (9). Specific endpoints were: 1) SCD (defined as
either witnessed instantaneous unexpected death occurring
without preceding symptoms or nonwitnessed unexpected
death, if other causes of death were excluded with reason-
able certainty [i.e., patients who had known signs, symp-
toms, or other fatal disease when last observed] or cardiac
death occurring 24 h after onset of cardiac symptoms
[e.g., acute pulmonary edema or cardiogenic shock]);
2) cardiovascular death (defined as death caused by compli-
cations of myocardial infarction, progressive heart failure,
cerebrovascular disease, complications of cardiac surgery or
intervention, other cardiac or cardiovascular diseases includ-
ing SCD as defined previously); 3) AVR (defined as AVR as
a single operative procedure or performed in combination
with other procedures); 4) hospitalization for incident con-
gestive heart failure (excluding patients after AVR, known
heart failure, aortic valve area 1.0 cm2, and/or known
eart disease, aside from AS, that could have contributed to
he development of heart failure); 5) nonfatal and fatal
yocardial infarction (defined as a typical increase and
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
BBB  bundle branch block
CI  confidence interval
HR  hazard ratio
LBBB  left bundle branch
block
LV  left ventricular
RBBB  right bundle
branch block
SCD  sudden cardiac
deathecrease in troponin or creatine kinase–myocardial band
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ischemic electrocardiographic changes (new pathologic Q
waves, ST-segment elevation, ST-segment depression,
inversion of T waves in at least 2 leads, and/or percuta-
neous coronary intervention with significant coronary
stenosis/thrombus).
Statistical analysis. Data were analyzed using the SAS
ersion 9.1 (SAS Institute, Cary, North Carolina). Contin-
ous data are expressed as mean  SD and categorical
variables as proportions. Continuous variables were nor-
mally distributed, except for QRS duration, which was
assessed as a categorical variable by assigning indicator
variables to QRS duration: 1) 85 ms; 2) 85 to 99 ms;
3) 100 ms (excluding patients with BBB); 4) LBBB; and
5) RBBB with and without left anterior fascicular block.
Due to suspected different etiology, patients with RBBB
were set aside for separate hypothesis-generating analyses.
Differences in continuous variables were evaluated by using
1-way ANOVA (with unweighted mean analysis due to
unequal sample sizes) and trend tests for categorical vari-
ables. To reduce the risk of type I error, pairwise compar-
isons with a reference group (QRS 85 ms) were adjusted
by Dunnett’s test for multiple comparisons. The impact of
the simvastatin/ezetimibe combination compared with pla-
cebo on progression in QRS duration was assessed in a
mixed model using repeated measures of annual in-study
electrocardiographic re-examinations. QRS duration as a
continuous and categorical variable (as defined earlier)
satisfied the linear and proportional hazard assumptions for
Cox time-to-event modeling. Associations of QRS dura-
tion, as a categorical variable, with all cause-mortality and
other endpoints (i.e., heart failure, AVR, acute myocardial
infarction, SCD, and cardiovascular death) were analyzed by
Cox models and by competing risk regression (using death
as a competing event), as described by Fine and Gray (16),
respectively. The effects are expressed by cause-specific
hazard ratio (HR) and 95% confidence interval (CI). Dif-
ferences in the incidence of SCD and overall cardiovascular
death among groups of QRS duration were evaluated by
log-rank tests. Multivariable relationships were determined
by adjusting for classic risk factors differing among the
groups of QRS duration and with significant univariate
impact on the investigated outcome, selected from stepwise
regression of age, sex, LV ejection fraction, LV mass indexed
by body surface area, and estimated glomerular filtration rate
([ml/min/1.73 m2]  186  [serum creatinine (mol/l) 
.011312]1.154  [age]0.203  [0.742 if female]). Addi-
ional measures were taken to avoid overfitting the multi-
ariable models; 1) QRS duration was investigated as
ovariate with 3 degrees of freedom (as defined), and
) computerized backward elimination was performed in all
odels in which QRS duration (as a categorical variable)
as a multivariable predictor (with p  0.05 needed to stay
in the model). All analyses were checked for the influence of
randomized treatment, but this did not alter the results, and
the covariate was not included in the final analyses (data notpresented). The additive prognostic value of QRS duration
was evaluated as described by Pencina et al. (17). Because
there is no established score system for SCD in asymptom-
atic AS, a priori risk categories of SCD were set at 0.9%
(expected occurrence in age- and sex-matched U.S. back-
ground) (18), 0.9% to 5%, and 5% (during the mean
follow-up of 4.3 years). To test whether the impact of QRS
duration on SCD was sensitive to the definition of SCD, an
additional analysis was performed using a breakdown of
SCD with and without preceding symptoms of heart failure
or angina in accordance with a modified Hinkle-Thaler
classification (19). Proportionality and linearity assumption
for all variables in the multivariable models were checked by
testing the dependence of their relative risk estimate over
time. There were no significant differences in the competing
event (noncardiovascular death) among groups of baseline
QRS duration and LBBB (data not presented); cumulative
incidence plots of SCD and cardiovascular death are there-
fore given as rates of the investigated endpoint per se.
Interaction terms were not included in the models because
there was no a priori suspicion of interaction. A 2-tailed p
value 0.05 was required for statistical significance.
Results
Baseline characteristics. Baseline electrocardiograms were
available for 1,563 patients; QRS duration could be assessed
in 1,542, missing values were due to 100% ventricular
pacing (n  10, 0.6%) or poor quality of electrocardiogram
(n 11, 0.7%), with no significant difference in distribution
of age, sex, peak aortic jet velocity, and LV mass between
patients with and without data for the current study (data
not presented). The study population consisted of 942 men
(61.1%) and 600 women (38.9%) followed for a mean of 4.3 
0.8 years, totaling 6,631 patient-years of follow-up. The
mean age was 67.4  9.6 years and the mean peak aortic jet
velocity was 3.1 0.5 m/s. Groups with QRS duration85
s (n  900, 58.3%), 85 to 99 ms (n  396, 25.7%), 100
s without BBB (n 144, 9.3%), and LBBB (n 43, 2.8%)
differed in the mean LV diameter in diastole and systole, LV
posterior wall thickness, intraventricular septal thickness, LV
ejection fraction, LV mass/body surface area, heart rate, body
mass index, cholesterol levels, and the proportion of women
and prevalence of hypertension (Table 1).
Clinical impact of baseline QRS duration and LBBB. A
total of 140 deaths occurred (9.4%); 68 were categorized as
cardiovascular (4.6%) and 27 as SCDs (1.8%, annual rate
0.4%), 428 patients were referred for AVR (28.9%), 36
experienced incident myocardial infarction (2.4%), and 34
were hospitalized for heart failure before AVR (2.3%).
End-of-study cumulative incidences according to QRS
duration and LBBB are given in Table 2, and the impact of
QRS duration 100 ms and LBBB, compared with those
with QRS duration85 ms, in Table 3. The annual rates of
SCD and overall cardiovascular death were, respectively,
0.2% and 0.8% in QRS duration 85 ms, 0.5% and 1.2%
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duration 100 to 119 ms compared with 0.6% and 1.1% in
LBBB. Considering QRS duration as a linear predictor, the
risk of SCD increased with 40% per 10 ms greater QRS
width (HR: 1.4; 95% CI: 1.1 to 1.7; p  0.005). Further
nalyses excluding patients with LBBB showed that the risk
f SCD increased 2.2-fold per 10 ms greater QRS width
HR: 2.2; 95% CI: 1.5 to 3.2; p  0.001). In multivariable
nalyses, patients with QRS duration of 100 to 119 ms had,
ompared with those with QRS duration 85 ms, a 5-fold
igher risk of SCD (95% CI: 1.8 to 13.7; p  0.002) and a
Baseline Demographics and Echocardiographic Characteristics AccTable 1 Baseline Demographics and Echocardiographic Charac
QRS <85 ms
(n  900)
Age, yrs 67.5 9.5
Male, % 51.0
Systolic blood pressure, mm Hg 144.3 20.5
Diastolic blood pressure, mm Hg 81.9 10.4
History of hypertension, % 47.4
Heart rate, beats/min 66.1 11.5
Body mass index, kg/m2 26.6 0.55
Peak aortic jet velocity, m/s 3.08 0.55
Mild aortic stenosis, %† 47.5
Aortic valve area/BSA, cm/m2 0.61 0.19
Sokolow-Lyon voltage, mV 26.5 0.6
Cornell voltage, mV 18.3 7.0
Cornell voltage duration product, mV  ms 1,467.5 44.1
Left anterior fascicular block, % 4.0
QRS axis, ° 18.8 32.4
Left ventricular mass/BSA, g/m2 93.0 25.5
Left ventricular ejection fraction, % 66.7 8.0
Posterior wall thickness, cm 0.84 0.17
Left ventricular dimension, cm 4.92 0.60
Left ventricular dimension in systole, cm 3.09 0.52
Relative wall thickness , LV posterior wall/LV internal radius 0.35 0.09
Intraventricular septal thickness, cm 1.10 0.26
Stroke index, ml/m(height)2.04 25.9 6.1
Estimated GFR, ml/min/1.73 m2 67.6 11.6
High-density lipoprotein cholesterol, mmol/l 1.54 0.44
Low-density lipoprotein cholesterol, mmol/l 3.60 0.87
Beta-blockers, % 48.7
Drugs acting on the renin-angiotensin system, % 39.3
Diuretics, % 43.6
Values are mean  SD or %. *p  0.05 compared with QRS duration 85 ms (Dunnett’s test). †
BSA  body surface area; GFR  glomerular filtration rate; LBBB  left bundle branch block.
End-of-Study Cumulative Incidence of Endpoints ATable 2 End-of-Study Cumulative Incidence of
QRS <85 ms
(n  900)
QRS 85
(n 
Sudden cardiac death 9 (1.0) 9 (
Cardiovascular death 31 (3.4) 21 (
Aortic valve replacement, 252 (28.0) 124 (
Heart failure 18 (2.0) 7 (
Myocardial infarction 21 (2.3) 8 (
All-cause mortality 73 (8.1) 43 (Values are n (%). *p  0.05 compared with QRS duration 85 ms (competin
LBBB  left bundle branch block..5-fold higher risk of cardiovascular death (95% CI: 1.2 to
.1; p  0.01). Stratifying the latter analysis by SCDs with
preceding symptoms (n  4, 2 admitted for heart failure in
RS duration 85 ms and 2 diagnosed with angina in
RS duration 100 to 119 ms), patients with QRS duration
00 to 119 ms remained, compared with those with QRS
uration85 ms, at a 4.7-fold higher risk of SCD (95% CI:
.7 to 13.1; p  0.003). Cumulative incidences of SCD and
ardiovascular death in groups of baseline QRS duration
nd LBBB are presented in Figures 1 and 2, respectively. Of
ll the variables included in the multivariable model, longer
g to QRS Duration and LBBBics According to QRS Duration and LBBB
S 85–99 ms
(n  396)
QRS 100–119 ms
(n  144)
LBBB
(n  43) Overall p Value
66.5 9.7 66.2 10.2 71.2 8.1* 0.01
72.0* 83.3* 65.1 0.001
46.2 19.5 146.8 20.8 144.4 21.7 0.30
82.4 10.9 82.5 10.2 80.0 10.6 0.50
57.3 57.6* 62.8* 0.001
64.1 10.2* 62.1 11.6* 62.2 9.8 0.001
27.2 4.4 27.6 4.4 27.6 4.0 0.04
3.09 0.55 3.13 0.52 2.97 0.54 0.36
46.1 37.2 57.1 0.08
0.61 0.19 0.58 0.17 0.62 0.23 0.30
27.9 0.9* 27.9 1.5 28.0 2.8 0.04
20.3 7.7* 23.7 9.3* 33.5 8.1* 0.001
23.0 67.2* 2,432.0 111.7* 4,464.7 202.3* 0.001
9.1* 25.0* — 0.001
12.8 36.7* 0.6 43.1* 25.0 22.9* 0.001
06.6 31.4* 118.3 39.2* 115.0 35.8* 0.001
64.5 10.0* 63.1 8.8* 62.3 8.6* 0.001
0.89 0.19* 0.95 0.20* 0.91 0.17* 0.001
5.22 0.60* 5.34 0.70* 5.22 0.71* 0.001
3.34 0.55* 3.49 0.64* 3.45 0.64* 0.001
0.35 0.09 0.36 0.09 0.36 0.08 0.32
1.18 0.29* 1.24 0.29* 1.22 0.25* 0.001
25.7 6.6 25.0 5.8 25.1 6.7 0.40
68.7 12.6 71.0 13.6* 67.3 11.8 0.02
1.47 0.40* 1.43 0.43* 1.50 0.42 0.005
3.50 0.90 3.40 0.82* 3.62 0.95 0.03
49.8 55.6 58.1 0.08
45.7* 36.8 55.8* 0.11
47.2 48.6 55.8 0.05
peak aortic jet velocity 2.5 to 3.0 m/s.
ing to QRS Duration and LBBBoints According to QRS Duration and LBBB
s QRS 100–119 ms
(n  144)
LBBB
(n  43)
Overall
p Value
8 (5.6)* 1 (2.3) 0.005
14 (9.7)* 2 (4.7) 0.009
43 (29.9) 9 (20.9) 0.28
6 (4.2) 3 (7.0)* 0.07
5 (3.5) 2 (4.7) 0.56
18 (12.5) 6 (14.0) 0.12ordinterist
QR
1
1,8
1ccordEndp
–99 m
396)
2.3)
5.3)
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predictors of SCD. Using backward elimination, longer
QRS duration (p 0.002 for an overall test of QRS groups,
QRS duration of 100 to 119 ms vs. 85 ms, HR: 6.4; 95%
CI: 2.5 to 16.7; p  0.001) and older age (HR: 1.06; 95%
I: 1.01 to 1.12; p  0.01) were both independently
ssociated with the risk of SCD. Similarly, in backward
limination of all covariates included in the model with
verall cardiovascular death as the outcome, longer QRS
uration (p  0.03 for an overall test of QRS groups, QRS
uration of 100 to 119 ms vs. 85 ms, HR: 2.8; 95% CI:
.4 to 5.6; p  0.003), older age (HR: 1.1 per 1 year; 95%
I: 1.1 to 1.1; p  0.001), and lower LV ejection fraction
HRs for QRS Duration 100 to 119 ms and LBBB Versus QRS DuratTable 3 HRs for QRS Duration 100 to 119 ms and LBBB Versu
Endpoint
QRS Duration 100–119 ms
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI)
Sudden cardiac death* 5.7 (2.2–14.9) 0.001 5.0 (1.8–13.7)
Cardiovascular death* 3.0 (1.6–5.5) 0.001 2.5 (1.2–5.1)‡
Aortic valve replacement* 1.2 (0.9–1.6) 0.29 1.0 (0.7–1.4)§
Heart failure* 2.2 (0.9–5.6) 0.09 1.3 (0.4–3.9)
Myocardial infarction* 1.5 (0.6–4.1) 0.39 2.1 (0.7–6.1)†
All-cause mortality* 1.6 (1.0–2.7) 0.07 1.4 (0.7–2.5)‡
Adjusted by covariates with significant univariate impact on investigated outcome: *Reference QR
mass indexed by body surface area, estimated glomerular filtration rate, and left ventricular ejecti
rate, left ventricular ejection fraction, and peak aortic jet velocity (did not differ between groups o
CI  confidence interval; HR  hazard ratio; LBBB  left bundle branch block.
Figure 1 Rate of Sudden Cardiac Death by QRS Group
Cumulative incidence of sudden cardiac death according to baseline QRS durationHR: 1.04 per 1% lower; 95% CI: 1.01 to 1.07; p  0.007)
emained as independent predictors. Adding QRS duration
s a categorical variable to a model with SCD as an outcome
nd age and LV mass indexed by body surface area as
ovariates increased the C index 2.6% (receiver-operating
haracteristic curve area shifted from 70.4% to 73.0%; p 
.02) and improved net reclassification index by 21.0% (p
.03). Almost all (92.6%) SCDs occurred before AVR;
dding AVR as a time-dependent covariate in a model with
ge, sex, randomized treatment, and QRS duration did not
ignificantly alter the impact of QRS duration on SCD. In
his model, AVR was not associated with a change in the
isk of SCD (p  0.30, based on 776 patient-years of
85 msS Duration <85 ms
Left Bundle Branch Block
p Value
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI) p Value
0.002 2.4 (0.3–19.2) 0.40 1.6 (0.2–13.0)† 0.65
0.01 1.4 (0.3–6.0) 0.62 0.9 (0.2–3.7)‡ 0.83
0.80 0.8 (0.4–1.5) 0.78 0.8 (0.4–1.7)§ 0.60
0.62 3.8 (1.1–12.8) 0.03 1.1 (0.2–4.9) 0.91
0.16 2.2 (0.5–9.2) 0.30 1.0 (0.1–7.7)† 1.00
0.32 1.8 (0.8–4.2) 0.15 0.9 (0.4–2.3)‡ 0.85
tion 85 ms. †Age and left ventricular mass indexed by body surface area. ‡Age, left ventricular
ion. §Age, sex, left ventricular mass indexed by body surface area, estimated glomerular filtration
uration). Age and left ventricular ejection fraction.
ft bundle branch block (LBBB) during 4.3 years of follow-up. HR  hazard ratio.ion <s QR
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infarction as a time-dependent covariate, the predictive
value of QRS duration was only marginally lower (QRS
duration 100 to 119 ms vs. 85 ms; HR: 5.9; 95% CI: 2.2
to 15.8; p  0.001). In this model, incident myocardial
nfarction was associated with a subsequent 4.6-fold higher
isk of SCD (95% CI: 1.0 to 20.9; p  0.05). One third of
SCDs occurred in patients who had progressed to severe
AS; distribution of AS severity before SCD in groups of
baseline QRS duration and LBBB is given in Table 4. Of
note, the average increase in QRS duration was 1 ms per
year, there was no detectable difference between patients
randomized to the simvastatin/ezetimibe combination ver-
sus placebo (p  NS). Similarly, there was no difference in
he risk of SCD between the 2 treatment arms (p  0.98).
Figure 2 Rate of Cardiovascular Death by QRS Group
Cumulative incidence of overall cardiovascular death according to baseline QRS du
AS Severity Before Sudden Cardiac Deathccording to Bas line QRS Du ation and LBBB*Table 4 AS S verity Before Sudde Cardiac DeathAccording to Baseline QRS Duration and LBBB*
AS Severity QRS <85 ms QRS 85–99 ms QRS 100–119 ms LBBB
Mild AS 1 (0.4)† 2 (2.3)† 1 (3.8)† 1 (6.7)†
Moderate AS 2 (0.5)† 6 (3.4)† 5 (7.5)† —
Severe AS 6 (2.2)† 1 (0.8)† 2 (3.9)† —
Values are n (%). Mild  peak aortic jet velocity 2.5 to 3.0 m/s; moderate; peak aortic jet
velocity3.0 to4.0 m/s; severe peak aortic jet velocity4.0 m/s. *Last known value of peak
ortic jet velocity before sudden cardiac death. †Incidence in the percentage of sudden cardiac
eaths in the cells defined by QRS characteristics and aortic stenosis severity.
AS  aortic stenosis; LBBB  left bundle branch block. brognostic value of QRS morphology in patients with
BB. At baseline, a total of 102 patients had QRS dura-
ion 120 ms, including 43 (42.1%) with LBBB, 39
38.2%) with isolated RBBB, and 20 (19.6%) with RBBB
nd left anterior fascicular block (left posterior fascicular
lock was not detected in patients with RBBB); 6 patients
ad QRS duration 140 ms and the widest QRS complex
as 160 ms (n  1). As shown in Table 5, there was no
difference in major baseline characteristics between patients
and LBBB during 4.3 years of follow-up. Abbreviations as in Figure 1.
Baseline Demographics and EchocardiographicCharacteristics of Participants With RBBBTable 5 Baseline Demographics and Ec ocardiographicCharacteristics of Participants With RBBB
Variable
RBBB
(n  39)
RBBB  LAFB
(n  20)
p
Value
Age, yrs 71.2 3.0* 72.2 4.1* 0.67
Male, % 82.1* 90.0* 0.39
Peak aortic jet velocity, m/s 3.25 0.18 3.10 0.24 0.34
Aortic valve area/BSA, cm/m2 0.60 0.06 0.60 0.08 0.97
Left ventricular mass/BSA, g/m2 104.6 8.6* 106.4 11.4* 0.84
Left ventricular ejection fraction, % 66.7 2.6 65.3 3.5 0.57
Posterior wall thickness, cm 0.93 0.06* 0.91 0.08 0.83
Left ventricular diastolic dimension, cm 4.98 0.20 5.17 0.26 0.28
Left ventricular systolic dimension, cm 3.12 0.17 3.30 0.23 0.30
Relative wall thickness, cm 0.38 0.03 0.36 0.04 0.57
Intraventricular septal thickness, cm 1.23 0.09* 1.22 0.11 0.95
Values are mean  SD or %. *p  0.05 compared with QRS duration 85 ms (Dunnett’s test).rationBSA  body surface area; LAFB  left anterior fascicular block; RBBB  right bundle branch
lock.
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impact of LBBB is presented in Tables 2 and 3. In
unadjusted analysis, patients with RBBB and left anterior
fascicular block had, compared with those with QRS dura-
tion 85 ms, a 4.6-fold higher risk of myocardial infarction
(95% CI: 1.1 to 19.5; p  0.04). This association was
nonsignificant in multivariable analysis (p  NS). There
were no SCDs in RBBB with or without left anterior
fascicular block. Compared with QRS duration 85 ms,
isolated RBBB was not associated with an increased risk of
any predefined endpoint.
Discussion
This study is, to the best of our knowledge, the first to
investigate the association of QRS duration with the risk of
cardiovascular morbidity and mortality in a large contem-
porary population of asymptomatic patients with mild to
moderate AS, and several of our findings add to current
knowledge. First, longer QRS duration is associated with
risks of SCD and overall cardiovascular death independent
of clinical and echocardiographic covariates. Second, among
patients with QRS duration 120 ms, only those with
LBBB or combined RBBB and left anterior fascicular block
have an increased risk of cardiovascular events.
Underlying mechanisms of SCD in relation to QRS
duration in patients with chronic pressure load are uncertain
but may reflect associations of increased QRS duration with:
1) adverse LV response to increased afterload above the
changes in LV mass per se (20); 2) myocardial scarring due
to chronic subendocardial ischemia and fibrosis (21), further
supported by the association with incident myocardial
infarction; and 3) a higher threshold for termination of
spontaneously occurring ventricular tachycardia in the pres-
ence of longer QRS duration (22). The latter hypothesis is
further supported by the fact that QRS morphology was, in
patients with QRS duration 120 ms, more important for
the risk of adverse outcome than that of QRS duration per
se. On the molecular level, cardiac conduction velocity is
affected by fibrosis, connexins, and ion channels, which,
among other mechanisms, are influenced by activity in the
renin-angiotensin system (23). Longer QRS duration could
therefore be an early sign of subclinical cardiac damage,
which may not be detectable by standard echocardiographic
examination. However, we have not found any studies
investigating the mechanism of QRS duration and risk of
SCD in asymptomatic patients with AS. In patients with
pressure overload due to hypertension, QRS duration has
been shown to be independently predictive of SCD (4). AS
symptoms and reduced LV systolic function were exclusion
criteria in the current study. This adds to evidence that QRS
duration and morphology are, independent of study popu-
lation, associated with a poor prognosis and, in particular,
the risk of SCD. Although differences in QRS duration
could result from less than severe AS, baseline abnormalities
may have had explanations other than AS. Indeed, this isquite likely, given the high prevalence of concomitant
systemic hypertension in this population (24). In addition,
the predictive value of QRS duration might have been
different in AS patients with subclinical ischemic heart
disease. However, even after adjusting by incident myocar-
dial infarction and simvastatin/ezetimibe compared with
placebo, QRS duration remained a highly significant pre-
dictor of SCD. Comparing the observed incidence of SCD
with an age- and sex-matched U.S. background population
(18), the rate of SCD in patients with QRS 85 ms seems
to resemble that in individuals without AS.
The different outcome in LBBB compared with RBBB
with and without left anterior fascicular block indicates first
that isolated RBBB does not predict adverse events in
patients with asymptomatic AS. Second, LBBB is not
associated with a greater risk of cardiovascular events in
patients with asymptomatic AS than moderate QRS pro-
longation alone. This concurs with recent data from the
general population, suggesting that BBB is not as strong a
predictor of arrhythmic death as prolonged QRS duration
not meeting criteria for BBB (25). A potential pathophys-
iological mechanism may be that BBB reflects a disturbance
in the conduction system, whereas longer QRS duration
without BBB reflects abnormal depolarization in the myo-
cardium itself.
Study limitations. In the SEAS population of asymptom-
atic patients with mild to moderate AS, relatively few
patients had QRS duration 120 ms, which may reflect
their exclusion from the study population due to symptom
onset or death. The latter hypothesis is consistent with the
increased rate of SCD associated with longer QRS duration
in the present study. The exclusion of AS patients with
symptoms, overt coronary artery disease, or previous heart
failure resulted in relatively small numbers of SCDs and
myocardial infarctions as well as small groups with LBBB or
RBBB. The low number of events resulted in wide confi-
dence intervals, the inability to build comprehensive multi-
variable analyses, and the risk of overfitted models. The
relatively low power to determine independent predictors of
hard endpoints should be kept in mind when interpreting
our findings.
Conclusions
In asymptomatic patients with AS, QRS duration is inde-
pendently associated with the risk of SCD and overall
cardiovascular death. Our findings suggest that QRS dura-
tion and morphology, as well as factors influencing these
parameters, should be included when estimating the risk
associated with watchful waiting and thus the need for
intervention in asymptomatic AS. The fair prognosis asso-
ciated with QRS 85 ms might suggest that early AVR is
not likely to have a significant benefit in reducing SCD in
these patients.
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